SAN DIEGO, March 2, 2025 /PRNewswire/ — Longbio Pharma (Suzhou) Co., Ltd. (referred to as “Longbio”), a leading biotech company dedicated to developing innovative biologic treatments for allergy, ...
Lipella Pharmaceuticals Inc. announced positive topline results from the second cohort of its Phase 2a clinical study of LP-310, a liposomal-tacrolimus oral rinse aimed at treating oral lichen planus ...
PHILADELPHIA, March 2, 2026 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. ("LongBio"), a clinical-stage biotech company focused on discovery and development of biologics targeting allergic and ...
The data to be presented includes safety and efficacy findings from the 0.25 mg and 0.50 mg dose cohorts of LP-310, administered once daily over four weeks in adults with symptomatic OLP. The primary ...
PITTSBURGH, April 08, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for ...
(RTTNews) - Biotechnology company Lipella Pharmaceuticals Inc. (LIPO) announced top line results for its recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results